Barbara S. Pender

1.7k total citations · 1 hit paper
19 papers, 451 citations indexed

About

Barbara S. Pender is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Barbara S. Pender has authored 19 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 6 papers in Molecular Biology and 5 papers in Genetics. Recurrent topics in Barbara S. Pender's work include CAR-T cell therapy research (17 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Viral Infectious Diseases and Gene Expression in Insects (5 papers). Barbara S. Pender is often cited by papers focused on CAR-T cell therapy research (17 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Viral Infectious Diseases and Gene Expression in Insects (5 papers). Barbara S. Pender collaborates with scholars based in United States, Canada and South Africa. Barbara S. Pender's co-authors include Stanley R. Riddell, Jordan Gauthier, David G. Maloney, Cameron J. Turtle, Alexandre V. Hirayama, Rachel N. Steinmetz, Aesha Vakil, Kevin A. Hay, Reed M. Hawkins and Alyssa Sheih and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Biology of Blood and Marrow Transplantation.

In The Last Decade

Barbara S. Pender

17 papers receiving 449 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

2020 227 citations Jordan Gauthier, Alexandre V. Hirayama et al. Blood profile →

Peers

Barbara S. Pender

ONCOL

PFM

GENET

Matthew L. Ulrickson United States

Tinh-Doan Phi United States

Christine Dehner United States

Yvette Bernal United States

Elizabeth Halton United States

Christina A. Bachmeier United States

Meg Elias United States

Jeff Aycock United States

Angela Hückelhoven‐Krauss Germany

Sophia Stock Germany

Matthew L. Ulrickson United States

Barbara S. Pender

313 ×0.8

ONCOL

156 ×1.1

PFM

70 ×0.6

GENET

66 ×0.6

GENET

77 ×0.7

Citations per year, relative to Barbara S. Pender Barbara S. Pender (= 1×) peers Matthew L. Ulrickson

Countries citing papers authored by Barbara S. Pender

Since Specialization

Citations

This map shows the geographic impact of Barbara S. Pender's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara S. Pender with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara S. Pender more than expected).

Fields of papers citing papers by Barbara S. Pender

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara S. Pender. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara S. Pender. The network helps show where Barbara S. Pender may publish in the future.

Co-authorship network of co-authors of Barbara S. Pender

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara S. Pender. A scholar is included among the top collaborators of Barbara S. Pender based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara S. Pender. Barbara S. Pender is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Gauthier, Jordan, Emily C. Liang, Jennifer J. Huang, et al.. (2025). Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL. Blood Advances. 9(8). 1861–1872.

Fiorenza, Salvatore, Erik L. Kimble, Alexandre V. Hirayama, et al.. (2023). Fully Human CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Results of a First-in-Human Phase I/II Study. Transplantation and Cellular Therapy. 29(2). S13–S13. 1 indexed citations

Gauthier, Jordan, Salvatore Fiorenza, Erik L. Kimble, et al.. (2023). Phase I Trial of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder for Adults with Relapsed/Refractory B-ALL. Transplantation and Cellular Therapy. 29(2). S99–S100.

Kimble, Erik L., Alexandre V. Hirayama, Barbara S. Pender, et al.. (2022). CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II Study. Blood. 140(Supplement 1). 10363–10365. 2 indexed citations

Hirayama, Alexandre V., Jordan Gauthier, Jenna Voutsinas, et al.. (2022). Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma. Blood. 140(Supplement 1). 7447–7449. 3 indexed citations

Gauthier, Jordan, Erik L. Kimble, Alexandre V. Hirayama, et al.. (2022). Efficacy and Safety of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder in Adults with Relapsed/Refractory B-ALL. Blood. 140(Supplement 1). 10360–10362. 1 indexed citations

Rezvani, Andrew R., Barbara S. Pender, Barry E. Storer, et al.. (2020). Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies. Biology of Blood and Marrow Transplantation. 26(10). 1811–1818. 4 indexed citations

Gauthier, Jordan, Cassie Chou, Alexandre V. Hirayama, et al.. (2020). High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics. Blood. 136(Supplement 1). 37–38. 8 indexed citations

Gauthier, Jordan, Alexandre V. Hirayama, Janaki Purushe, et al.. (2020). Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 135(19). 1650–1660. 227 indexed citations breakdown →

10.

Gauthier, Jordan, Evandro D. Bezerra, Alexandre V. Hirayama, et al.. (2020). Repeat Infusions of CD19 CAR-T Cells: Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival. Biology of Blood and Marrow Transplantation. 26(3). S267–S268. 2 indexed citations

11.

Hirayama, Alexandre V., Jordan Gauthier, Kevin A. Hay, et al.. (2019). High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood. 134(7). 636–640. 121 indexed citations

12.

Bezerra, Evandro D., Jordan Gauthier, Alexandre V. Hirayama, et al.. (2019). Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells. Blood. 134(Supplement_1). 201–201. 2 indexed citations

13.

Hirayama, Alexandre V., Jordan Gauthier, Kevin A. Hay, et al.. (2019). HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPHOMA AFTER CD19 CAR‐T CELL IMMUNOTHERAPY. Hematological Oncology. 37(S2). 170–171. 23 indexed citations

14.

Gauthier, Jordan, Alexandre V. Hirayama, Kevin A. Hay, et al.. (2019). Durable responses after CD19‐targeted CAR‐T cell immunotherapy with concurrent ibrutinib for CLL after prior ibrutinib failure. Hematological Oncology. 37(S2). 168–170. 1 indexed citations

15.

Hay, Kevin A., Jordan Gauthier, Alexandre V. Hirayama, et al.. (2018). Factors impacting disease-free survival in adult B cell B-ALL patients achieving MRD-negative CR after CD19 CAR-T cells.. Journal of Clinical Oncology. 36(15_suppl). 7005–7005. 2 indexed citations

16.

Hirayama, Alexandre V., Jordan Gauthier, Kevin A. Hay, et al.. (2018). Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. Blood. 132(Supplement 1). 1680–1680. 30 indexed citations

17.

Gauthier, Jordan, Alexandre V. Hirayama, Kevin A. Hay, et al.. (2018). Factors associated with duration of response after CD19-specific CAR-T cell therapy for refractory/relapsed B-cell non-Hodgkin lymphoma.. Journal of Clinical Oncology. 36(15_suppl). 7567–7567. 6 indexed citations

18.

Gauthier, Jordan, Alexandre V. Hirayama, Kevin A. Hay, et al.. (2018). Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma. Blood. 132(Supplement 1). 1415–1415. 5 indexed citations

19.

Pender, Barbara S., et al.. (1996). Transforming growth factor beta 1 alters rat peritoneal macrophage mediator production and improves survival during endotoxic shock.. PubMed. 7(2). 137–42. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact